Last checked at 13 Apr 2023 16:30
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Faron to Present at Canaccord Horizons in Oncology Virtual Conference
Press release, April 13, 2023
TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on tackling cancers via immunotherapy, today announces that Chief Executive Officer, Dr. Markku Jalkanen and Chief Medical Officer, Dr. Marie-Louise Fjällskog, will present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 20 at 8 AM EST.
Faron will present on the panel, "Boosting checkpoint inhibitors - finally two solutions?". Dr. Jalkanen and Dr. Fjällskog will discuss the most recent data for bexmarilimab, the company's wholly owned immunotherapy asset, for treating hematological malignancies and solid tumors.
For more information please contact:
Investor Contact
Faron Pharmaceuticals
Julia Balanova
VP, Investor Relations
julia.balanova@faron.com
investor.relations@faron.com
Phone: +1 (917) 306-6096
Media Contact
Faron Pharmaceuticals
Jennifer C. Smith-Parker
Head of Communications
Jennifer.Smith-Parker@faron.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker Christopher Golden, James SteelPhone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North Juha KarttunenPhone: +358 (0)40 555 4727Jukka JärveläPhone: +358 (0)50 553 8990
Consilium Strategic Communications Mary-Jane Elliott, David Daley, Lindsey Neville faron@consilium-comms.com Phone: +44 (0)20 3709 5700
About Bexmarilimab
Bexmarilimab is Faron's wholly owned, investigational immunotherapy with the potential to provide immune stimulation for treatment-resistant cancers through targeting myeloid cell function. A novel anti-CLEVER-1 humanised antibody, bexmarilimab targets CLEVER-1 positive (Common Lymphatic Endothelial and Vascular Endothelial Receptor 1) tumor-associated macrophages (TAMs) in the tumor microenvironment, converting highly immunosuppressive M2 macrophages to immune-stimulating M1 macrophages. As an immuno-oncology therapy, bexmarilimab has therapeutic potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules in both solid tumors and hematologic malignancies.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) together with its subsidiaries, is a clinical stage biopharmaceutical group focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation. Bexmarilimab, a novel anti-CLEVER-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with hematological cancers and untreatable solid tumors, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. In terms of other pipeline assets, Traumakine® is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of hyperinflammatory conditions. Faron is headquartered in Turku, Finland. Further information is available at www.faron.com.